Global Osteoporosis Therapeutics Market to Reach US$11.1 Billion by 2010, According to New Report by Global Industry Analysts

Share Article

Worldwide osteoporosis therapeutics market is projected to reach US$11.1 billion in sales by 2010. Aging population, continuing new product introductions, growing awareness of osteoporosis, and expansion of bone densitometry scanning are the prime growth drivers in the worldwide osteoporosis therapeutics market. However with the launch of newer treatments coupled with the patent expiry of major drugs including Fosamax, Actonel, and Boniva, growth in the market for osteoporosis therapeutics is expected to slow down by 2015.

Osteoporosis Therapeutics: A Global Strategic Business Report

Osteoporosis, the most common type of metabolic bone diseases, is an implacable epidemic growing rapidly in regions of North America, Europe, and Japan. Afflicting over 200 million people across the world, the potentially life-threatening disease - osteoporosis poses a major clinical challenge to the medical world. Major therapeutic classes currently available include bisphosphonates, Estrogen Replacement Therapy (ERT) drugs, calcitonins and Selective Estrogen Receptor Modulators (SERMs). Parathyroid Hormone (PTH)-based drugs comprise the most recent genre of therapeutics with new bone-forming potential. As osteoporosis is asymptomic, several cases of osteoporosis are detected only after experiencing a fracture.

United States and Europe dominate the global Osteoporosis therapeutics market, collectively capturing more than 82% of the sales for 2007, as stated by recent report published by Global Industry Analysts, Inc. Bisphosphonates market, accounts for lion's share of the worldwide osteoporosis therapeutics market, is expected to cross US$6.1 billion by 2009. As the controversies surrounding estrogen/hormone replacement therapy (ERT/HRT) continue to baffle the medical profession, bisphosphonates emerge as the most preferred therapeutic modality for osteoporosis prevention and treatment. Fosamax and Actonel are the leading bisphosphonates available to effectively prevent and treatment osteoporosis. Continuous research in bisphophonates arena brought to light newer class of intravenous bisphosphonates such as Zoledronic Acid and Pamidronate. However, bisphosphonates show a different course of action on jawbone predominantly in patients with weaker immune systems. P&G's Actonel/ Sanofi-Aventis and Merck's Fosamax are expected to continue their dominance over market for bisphosphonates, until generic forms of Fosamax make their way into the market in 2008.

SERMs market is anticipated to be the most sought after drug class in the coming years. Anticipated new product introductions such as Pfizer's lasofoxifene and Wyeth's basedoxifene are expected to drive the market.

The osteoporosis market is still largely untapped, with only about a third of osteoporosis patients being diagnosed and treated for the condition, which opens up a wide range of opportunities for pharmaceutical companies.

Traditional remedies such as calcium supplements, vitamin D and calcitonins are likely to take a backseat, while newer bone-forming agents are poised to take charge of the osteoporosis therapeutic arena, mainly dominated by anti-resorptive drugs.

Major players profiled in the report include Eli Lilly and Company, F.Hoffmann-La Roche Ltd, Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Organon International, Procter & Gamble Pharmaceuticals Inc., Sanofi-Aventis SA, Servier SA, Solvay Pharmaceuticals Inc., Unigene Laboratories, Inc. and Wyeth.

The report titled "Osteoporosis Therapeutics: A Global Strategic Business Report" published by Global Industry Analysts, Inc., analyzes current and future market prospects over the review period 2001-2015. The report throws light on industry overview, trends and issues governing worldwide and regional market, an insight into major therapeutic classes, product overview, new drugs on the cards, and major clinical findings/trials. Also enumerated are product launches/innovations and recent strategic corporate activity of major market participants.

For more details of this research report please visit http://www.strategyr.com/Osteoporosis_Therapeutics_Market_Report.asp

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs more than 700 people worldwide and publishes more than 880 full-scale research reports each year. Additionally, the company also offers a range of more than 60,000 smaller research products including company reports, market trend reports and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.
Telephone 408-528-9966
Fax 408-528-9977
Email press@StrategyR.com
Web Site http://www.StrategyR.com

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Public Relations
Visit website